Introduction
Sickle cell disease originates from a single nucleotide mutation of β-globin, which leads to polymerization of the mutated hemoglobin upon deoxygenation, and dramatic alteration in the shape and surface properties of red blood cells (RBCs).
Through interactions with multiple blood and immune cell populations, sickle
RBCs promote inflammation, obstruct the vasculature, and injure the endothelium, leading to broad manifestations that affect most vital organs. [1] [2] [3] [4] Although the molecular origin of the disease is clear, the mechanisms that contribute to the complex manifestation and severe outcome of the disease have not been fully elucidated. Recent studies have revealed that many cell types that are not affected by the β-globin mutation play important roles in the pathophysiology of SCD, 5 leading to an evolving multicellular paradigm that has triggered enthusiastic investigations into novel therapeutics for the disease.
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Neutrophils in Sickle Cell Disease
Neutrophils are a critical component of innate immunity. As the most abundant immune cells in the circulation, they provide immune protection against invading pathogens but can also promote certain inflammatory diseases. 6, 7 Neutrophils are initially suggested to promote disease progression in SCD by clinical epidemiological studies. SCD patients were found to exhibit marked variation in disease severity. For example, in patients with painful crises, the most common disease manifestation, the rates of crises vary from 0 to >10 episodes per year. 8, 9 Notably, patients with more severe clinical manifestations tend to have higher neutrophil counts compared to racially matched controls. 10 High leukocyte counts also positively correlate with early death, silent brain infarcts, hemorrhagic strokes and acute chest syndrome (ACS) in SCD patients, [11] [12] [13] [14] implicating leukocyte count (neutrophil in particular) as a major risk factor for SCD.
Further evidence supporting a role for neutrophils in SCD pathophysiology comes from the identification of myeloid growth factors, granulocyte macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF), as absolute contraindications in SCD individuals. In early reports, severe or fatal crises have occurred in SCD patients administered with either GM-CSF or G-CSF to treat leg ulcer, mobilize hematopoietic stem cells (HSCs) or correct neutropenia. [15] [16] [17] [18] More recently, a patient was reported to have a rare coexistence of SCD and severe congenital neutropenia, exhibiting significantly alleviated disease manifestations compared to his siblings. However, when the For personal use only. on October 24, 2017 . by guest www.bloodjournal.org From patient received G-CSF to treat neutropenia, the course of the disease dramatically worsened. 19 By contrast, reduction in neutrophil count can benefit SCD. In a multi-center study of hydroxyurea (MSH), hydroxyurea treatment − the most commonly used therapeutics for SCD patients − markedly decreased the frequency of painful crises and ACS in patients with moderate to severe SCD. 20 Hydroxyurea has been shown to effectively induce fetal hemoglobin (HbF) expression in RBC, but it has also many other effects that benefit SCD. [21] [22] [23] [24] For example, hydroxyurea treatment significantly decreases soluble VCAM-1 levels in patient plasma, and reduces adhesion of sickle RBCs to the endothelium. 22, 23 In addition, recent studies suggest that hydroxyurea treatment increases nitric oxide (NO) species, which may or may not be associated with induction of HbF. 21, [25] [26] [27] Interestingly, hydroxyurea treatment shows beneficial effects even in patients with no detectable rise of HbF, whereas all patients that respond well clinically to hydroxyurea treatment exhibit decreased numbers of neutrophils. 22, 28, 29 Neutrophils from patients with SCD also exhibit an activation phenotype characterized by lower expression level of L-selectin (CD62L) and higher level of CD64. 30 In addition, CD11b/CD18 membrane expression is also approximately 70% higher on neutrophils from SCD patients compared to controls. 31 These neutrophils show increased adhesive properties, which could be reduced by stimulation of the NO/cGMP-dependent pathways. 32 Hydroxyurea treatment is 33 Further studies suggest that hydroxyurea treatment has immediate benefits on sickle cell vaso-occlusion by inhibiting neutrophil recruitment and activation, with a mechanism that involves the amplification of the NO-cGMP pathway. 25, 26 These findings suggest an important role of neutrophils in the pathophysiology of SCD.
Neutrophil-RBC Interactions Promote Vaso-occlusion
The first evidence that neutrophils may directly participate in the pathogenesis of SCD comes from the observation that sickle RBCs bind to neutrophils in vitro.
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This observation is supported by in vivo studies in SCD mice (Berkeley mice 34 ),
where the dynamics of circulating blood cells are analyzed in the cremasteric microcirculation using intravital microscopy. 35 In this model, sickle RBCs are found to predominantly interact with adherent leukocytes in post-capillary venules. These interactions are triggered by surgical trauma, enhanced and sustained by TNF-α administration, leading to a lethal vaso-occlusive crisis (VOC). Mice lacking both P-and E-selectins, in which leukocytes are prevented from recruitment to the endothelium, are protected from VOC in this model. 35 Further studies using multichannel fluorescence intravital microscopy (MFIM) 
Neutrophil Heterogeneity and Microbiota Regulation
Circulating neutrophils have long been considered a homogenous population.
However, heterogeneity may arise from their aging in the circulation and replenishment by newly released neutrophils from the bone marrow. 38 Interestingly, neutrophil aging is driven by microbiota-derived signals through neutrophil toll-like receptors (TLRs) and Myd88-mediated signaling (Fig.1) .
Microbiota depletion or genetic deficiency of these signaling pathways leads to reduced aged neutrophil numbers and diminished Mac-1 activation in the vasculature. In SCD mice, the aged neutrophil population is dramatically expanded, and the increased aged neutrophil counts correlate positively with neutrophil adhesion, Mac-1 activation and neutrophil-RBC interactions.
Microbiota depletion using broad spectrum antibiotics largely normalizes the numbers of aged neutrophils in SCD mice and markedly reduces neutrophil adhesion, Mac-1 activation and neutrophil-RBC interactions, leading to significantly improved blood flow and prolonged survival. In addition, chronic depletion of the microbiota protects SCD mice from tissue damage. For example, splenomegaly and liver damage induced by SCD are significantly alleviated in antibiotics-treated SCD mice 39 .
Patients with SCD have also been analyzed for aged neutrophil numbers. 39 Consistent with the rodent data, the numbers of aged neutrophils are dramatically increased in SCD patients compared to healthy controls. Strikingly, in the patient population taking penicillin prophylaxis, the numbers of aged neutrophils are significantly reduced. 39 Although penicillin V can clearly prevent morbidity and mortality from Streptococcus pneumoniae infection in young children with SCD 40, 41 , whether antibiotics can mitigate vaso-occlusive episodes 
Platelets in Sickle Cell Disease
Platelets are essential for hemostasis but can also promote inflammation. 42 Platelet activation is elevated in SCD patients under steady-state condition, which is further enhanced during VOC. [43] [44] [45] Activated platelets may promote the adhesion of sickle RBCs to human vascular endothelium by secreting thrombospondin, 46 and may contribute to thrombosis and pulmonary hypertension in SCD. 43 Platelets can also bind to erythrocytes, monocytes and neutrophils to form aggregates. 45, 47 Significantly more platelet-monocyte aggregates and platelet-neutrophil aggregates are observed in the circulation of both SCD patients and transgenic SCD mice compared to controls. 48 Activated platelets bind to neutrophils to form aggregates in a P-selectin-dependent manner. 49 Pulmonary dysfunction is significantly ameliorated in SCD mice when platelet-neutrophil aggregate formation is blocked by P-selectin neutralizing antibody or the platelet inhibitor Clopidogrel. 49 At the molecular level, the serine/threonine kinase isoform AKT2 in neutrophils appears essential for neutrophil crawling and neutrophil-platelet interactions on activated endothelial cells during vascular inflammation. 50 Inhibition of AKT2 diminishes neutrophil adhesion and neutrophil-platelet interactions, leading to improved blood flow in SCD mice. 50 For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Platelets can also be captured by activated Mac-1 integrin clustered on the leading edge of adherent neutrophils, promoting vascular damage and lung injury by generating oxidative species in a mouse model of transfusion-related acute lung injury (TRALI). 37 In addition, platelet interaction can also induce neutrophil polarization through P-selectin glycoprotein ligand-1 (PSGL-1) transduced signals, triggering directed migration of neutrophils to initiate inflammation.
51
Although these studies indicate a role for platelets in the pathogenesis of SCD, direct evidence that platelets participate in major complications such as vasoocclusion in SCD is still lacking. Our own studies have found surprisingly little platelet accumulation at sites of active VOC (P.S.F., unpublished data).
Hemolysis, NETs, and Acute Lung Injury
Hemolysis in SCD arises from damaged sickle RBC membranes, causing chronic anemia and the release of hemoglobin into the circulation, which promotes inflammation by depleting NO, generating oxidative stress, and releasing heme, the prosthetic moiety of hemoglobin. 52 A large fraction of extracellular heme is carried by the erythrocyte-derived microparticles in circulation. 53 These hemeloaded microparticles transfer heme to endothelial cells, leading to vascular dysfunction and vaso-occlusion in SCD. 53 Activation by extracellular heme increases expression of adhesion molecules on endothelial cells, thus promoting leukocyte recruitment. 54 Heme can also contribute to the pathogenesis of SCD by activating placenta growth factor (PlGF) production from erythroid cells via erythroid Krüppel-like factor. 55 Recent studies have found that plasma heme levels are elevated during VOC in both human patients and SCD mice, leading to neutrophil activation and the formation of NETs in pulmonary vaculature. 56 NETs in pulmonary vasculature contribute to acute lung injury in SCD mice challenged with TNF-α, which is significantly alleviated by administration of DNAse I or hemopexin, the reagent that dismantles NETs or scavenges heme, respectively. 56 Administration of exogenous heme or hemin, the oxidized form of heme, can trigger VOC or ACS in SCD mice through activation of the endothelium, which is largely prevented by TLR4 inhibition, suggesting that extracellular heme/hemin may signal through TLR4 to trigger an inflammatory response. 57, 58 In addition, hemolytic transfusion reactions (HTRs) induce lethal acute vaso-occlusion in a model of alloimmune, IgG-mediated HTRs in SCD mice. 59 These studies suggest that VOC and acute lung injury may be interconnected by neutrophils, NETs, and hemolysis.
Platelets can also activate neutrophils to produce NETs. During bacterial infection, platelets are activated by TLR4 ligand in the circulation, and then bind to the adherent neutrophils, leading to the formation of NETs in liver sinusoids and pulmonary capillaries. 60 Platelets also promote NET formation in TRALI. 61 Targeting platelets activation with aspirin or a glycoprotein IIB/IIIA inhibitor reduces NET formation and alleviates lung injury. 61 Similarly, aspirin inhibits neutrophil-platelet aggregate formation and thereby protects the lungs in an acute lung injury model. 62 These studies raise a possibility that platelets may contribute to SCD pathophysiology by promoting NET formation, although direct evidence is still needed.
Inflammation in Sickle Cell Disease
SCD has long been recognized as a chronic inflammatory disease. Accumulating evidence reveals that cell types not affected by the mutation, such as leukocytes and endothelial cells, play important roles in SCD pathophysiology. In addition, the list of molecules that promote inflammation in SCD is also expanding (Fig.2) .
Cells that promote inflammation in SCD:
Monocytes exhibit an activated phenotype and promote inflammation in SCD. [63] [64] [65] Monocytes from SCD patients can activate NF-κB pathway in endothelial cells.
The activation of NF-κB pathway results in higher expression of adhesion molecules, including E-selectin, ICAM-1, VCAM-1, thus promoting mononuclear leukocytes adhesion to endothelial cells. The activation of endothelial cells by monocytes does not require cell-cell contact, but is mediated pro-inflammatory cytokines produced by monocytes. When TNF-α and IL-1β from monocytes are blocked with neutralizing antibodies, the upregulation of E-selectin expression by endothelial cells is abrogated. 63 Importantly, monocytes isolated from SCD patients have higher TNF-α and IL-1β expression levels compared to healthy controls. 64 Although the mechanisms that contribute to monocyte activation in SCD remain largely unclear, recent studies have identified several molecular and cellular factors important for this phenomenon. The first clue has emerged from the studies showing that platelet binding to monocytes leads to monocyte activation. 66 The percentage of platelet-monocyte aggregates is significantly higher in SCD patients compared to healthy controls, suggesting an increased activation level of monocytes. 66 The elevated levels of PlGF in SCD patients also contribute to monocytes activation. 67 
Molecules that promote inflammation in SCD:
Pro-inflammatory cytokines play critical roles in the pathophysiology of SCD.
SCD patients exhibit higher levels of several pro-inflammatory cytokines, including TNF-α, IL-6, IL-1β, GM-CSF, IL-3, endothelin-1 and prostaglandin E2. [80] [81] [82] [83] [84] Pro-inflammatory cytokines activate endothelial cells and leukocytes through the NF-κB pathway. 66 The activation of NF-κB pathway results in increased expression of endothelial adhesion molecules, such as ICAM-1, VCAM-1, P-selectin and E-selectin, promoting leukocyte adhesion and triggering the ensuing vaso-occlusive events. 82 For example, TNF-α alone with surgical trauma is enough to trigger lethal acute vaso-occlusion in transgenic SCD mice. 35 For
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Chemokines are a family of small molecules that can induce chemotaxis. 85 Chemokines contribute to SCD pathogenesis by acting on leukocytes. 59 In NY1DD SCD mice, higher levels of CXCL9 and CXCL10 are observed in the lung. 70 
Emerging Therapies targeting Neutrophils, Platelets and

Inflammatory Pathways in Sickle Cell Disease
Since polymerization of the abnormal hemoglobin represents a key step in the pathophysiology of SCD, it has been an important therapeutic target for over five decades. Any agents directly inhibiting this step, by HbF induction or by other mechanisms, will have numerous downstream effects on adhesion and inflammation. Our current understanding of the critical role of other cell types besides RBCs and key inflammatory processes, have led to the development of novel targeted therapies that are summarized below.
Targeting neutrophils:
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Hydroxyurea, the only FDA approved therapy for SCD, is a potent inducer of HbF. 106 However, hydroxyurea has multiple mechanisms by which it produces its clinical response. The Evidence-Based Management of Sickle Cell Disease:
Expert Panel Report 2014 (available at http://www.nhlbi.nih.gov/healthpro/guidelines/sickle-cell-disease-guidelines/) recommends dose escalation of hydroxyurea to achieve mild myelosuppression (absolute neutrophil count 2,000/uL to 4,000/uL) based on aggregate clinical and laboratory parameters. This is often accompanied by reduction in baseline thrombocytosis. While both of these effects may independently contribute to its clinical efficacy, they also affect the maximum tolerated dose, a clear predictor of HbF response. 107 It is also interesting to note that short-term administration of either hydroxyurea or the phosphodiesterase 9 (PDE9) inhibitor ameliorates VOC in a SCD murine model via NO-mediated cGMP elevating effects that lead to reduced neutrophil adhesion and heterotypic RBC-neutrophil interactions, suggesting that hydroxyurea may have immediate benefit in the setting of VOC. 26 PDE9 is highly expressed in hematopoietic cells and is thus a promising therapeutic target.
PF04447943, a PDE9 inhibitor is currently being evaluated in a phase I study (NCT02114203).
Rivipansel (GMI-1070), a synthetic pan-selectin inhibitor, has been shown to inhibit predominantly E-selectin-mediated leukocyte adhesion and dramatically reduce RBC-leukocyte interactions, leading to improved blood flow and prolonged survival in SCD mice during VOC. 79 In a phase I clinical trial, GMI-
has been well tolerated without significant adverse effects. SCD patients receiving GMI-1070 exhibited a modest increase in total peripheral white blood cell count without clinical symptoms. 108 Results of a prospective multicenter, randomized, placebo-controlled, double-blind, phase II study of 76 SCD patients with acute VOC reveals a positive, but non-significant trend, in the primary endpoint of time to VOC resolution in GMI1070 compared to placebo and a clinically significant decline of 63 hours (48%) in median values. 109 In addition, an 83% reduction of opioid use (p=0.01) in the active arm has been noted.
Currently, a phase III clinical trial of rivipansel in SCD is registered (NCT02187003). suggesting an important role of SHP-1 signaling in regulating neutrophil adhesion and activation. 112 IVIG administration in SCD patients in a phase I study demonstrates no significant adverse events with doses up to 800mg/kg, indicating safety and tolerability in acute VOC. 113 Since lower doses show better biomarker and clinical efficacy profiles, the 400mg/kg dose is selected for further study in an ongoing phase II trial (NCT01757418).
Intravenous immunoglobulin (IVIG)
Numerous preclinical and early phase clinical studies have demonstrated the benefit of targeting P-selectin. 114 The efficacy of SelG1, a humanized anti-Pselectin monoclonal antibody, in reduction of pain crises rates is currently being tested in an ongoing phase II trial (NCT01895361). Heparins also act via the inhibition of P-selectin-mediated adhesion 115 in addition to inhibition of ligand binding to leukocyte integrin Mac-1 116 and other anti-inflammatory effects 117 . This is in addition to their expected anticoagulant effect. Tinzaparin, a low molecular weight heparin, has been studied in a randomized double-blind clinical trial. 253 subjects were enrolled, ages 12 years and older, in a study in which reduced duration of VOC and no severe bleeding complications were reported. 118 A feasibility study of unfractionated heparin in acute chest syndrome is currently recruiting (NCT02098993).
Targeting platelets:
Prasugrel is a thienopyridine P2Y12 adenosine diphosphate (ADP) receptor antagonist that inhibits ADP-mediated platelet activation and aggregation.
Randomized double-blind placebo-controlled phase II studies to examine safety have been completed in adults. 119 Mean pain rates (percentage of days with pain) and intensity in the prasugrel arm are decreased compared with placebo.
However, these reductions do not reach statistical significance. Platelet surface
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From P-selectin and plasma soluble P-selectin, biomarkers of platelet and endothelial activation, are significantly reduced in SCD patients receiving prasugrel compared with placebo. Prasugrel is generally well tolerated and a phase III trial in children is ongoing (NCT01794000). Ticagrelor is a novel antiplatelet agent that also inhibits ADP-mediated platelet activation, but unlike Prasugrel, does not require metabolic activation. A phase II trial is currently registered (NCT02482298).
Targeting inflammation:
Regadenoson is an A 2A receptor (A 2A R) agonist reported in a phase I study in SCD patients to reduce iNKT cell activation to levels noted in healthy controls and SCD patients at baseline. 75 Notably, iNKT cell activation is associated with increased phosphorylation of NFκB p65, increased expression of A 2A R and higher levels of IFN-γ. Although NFκB p65 phosphorylation was reduced to baseline levels, the reduction in A 2A R expression and IFN-γ levels did not reach statistical significance. 75 No toxicity has been noted. Based on these positive findings in the biological endpoints, a phase II randomized placebo-controlled trial is currently recruiting (NCT01788631).
Several additional agents targeting inflammation via modulation of oxidant stress, nitric oxide bioavailability, coagulation and inflammatory cytokines are listed in 
Conclusion
In summary, advances in the understanding of the pathophysiology of sickle VOC have led to several new exciting agents that are currently being evaluated.
Given the complexity and multiplicity of events leading to the vaso-occlusive event, it is likely that a multi-targeted multi-modal approach will be required to achieve the best outcome.
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